When all is said and done, there may have been more losers than winners in last week's bizarre "rally" in the shares of the cancer-drug firm EntreMed. The stock began the week at $12 and ended at $33 1/4, a tidy 177% runup. But in the process, the company's 12 million shares outstanding changed hands an average of four times each--at prices up to $85. Sure, anyone who bought the stock more than a week ago received a windfall. But, in theory, there are three times as many people who got creamed. Cancer could well be eradicated before some of those...
To continue reading:
or
Log-In
